Activation of GPER-1 Attenuates Traumatic Brain Injury-Induced Neurological Impairments in Mice.

Mol Neurobiol

Department of Neurosurgery, Tangdu Hospital, Fourth Military Medical University, No. 569 Xinsi Road, Baqiao District, Xi'an, 710038, Shaanxi, China.

Published: August 2024

AI Article Synopsis

  • The study explored how G1, a GPER1 agonist, affects neurological issues and inflammation in mice with traumatic brain injury (TBI).
  • G1 treatment led to reduced brain swelling and blood-brain barrier damage, while also improving anxiety and cognitive function in TBI mice.
  • Findings revealed that G1 administration decreased harmful inflammation markers and promoted beneficial microglial activation, suggesting a role in mitigating cognitive deficits post-TBI.

Article Abstract

This study aimed to investigate the effects of G1-activated G protein-coupled estrogen receptor 1 (GPER1) on neurological impairments and neuroinflammation in traumatic brain injury (TBI) mice. The controlled cortical impingement (CCI) method was used to establish the TBI model. The mice were subjected to ovariectomy (OVX) for two weeks prior to modeling. GPER1 agonist G1 was administered by intracerebroventricular injection. Brain tissue water content was detected by wet/dry method, and blood-brain barrier damage was detected by Evans blue extravasation. The neurological impairments in mice were evaluated by open field test, Y-maze test, nest-building test, object location memory test and novel object recognition test. Ionized calcium-binding adapter molecule 1 (Iba1) staining was used to indicate the activation of microglia. Expression of M1/M2-type microglia markers and inflammatory factors were evaluated by ELISA and qRT-PCR. The G1 administration significantly reduced cerebral edema and Evans blue extravasation at injury ipsilateral cortex and basal ganglia in TBI mice. Activation of GPER1 by G1 improved the anxiety behavior and the cognitive dysfunction of mice induced by TBI. G1 administration significantly decreased Iba1-positive staining cells and the mRNA levels of CD86, macrophage cationic peptide 1 (Mcp-1), nitric oxide synthase 2 (Nos2), interleukin 1 beta (IL-1β), and macrophage inflammatory protein-2 (MIP-2), while increased the mRNA levels of interleukin 10 (IL-10), arginase1 (Arg-1) and CD206. Activation of GPER1 through G1 administration has the potential to ameliorate cognitive dysfunction induced by TBI in mice. It may also inhibit the activation of M1 microglia in cortical tissue resulting from TBI, while promoting the activation of M2 microglia and contributing to the regulation of inflammatory responses.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12035-024-03919-wDOI Listing

Publication Analysis

Top Keywords

neurological impairments
12
tbi mice
12
activation microglia
12
traumatic brain
8
impairments mice
8
evans blue
8
blue extravasation
8
activation gper1
8
cognitive dysfunction
8
induced tbi
8

Similar Publications

West Nile Neuroinvasive Disease: Case Series and Review of the Literature.

Am J Ther

January 2025

Department of Medicine, Long Island Jewish Forest Hills (Northwell Health), Forest Hills, NY.

Background: West Nile virus (WNV), although underdiagnosed, is the most common mosquito-borne disease and the second most common cause of viral encephalitis in the United States. Fewer than 1% of those infected develop neuroinvasive disease.

Methods: We present a cluster of 3 cases of neuroinvasive WNV that occurred between August and September 2023 and a review of the literature for neurologic involvement with this virus.

View Article and Find Full Text PDF

Alzheimer's disease (AD) is a progressive neurological condition characterized by a loss in cognitive functions, with no disease-modifying medication now available. It is crucial for early detection and treatment of Alzheimer's disease before clinical manifestation. The stage between cognitively healthy older persons and AD is known as mild cognitive impairment (MCI).

View Article and Find Full Text PDF

Beta-propeller Protein Associated Neurodegeneration (BPAN) is a devastating neurodevelopmental and neurodegenerative disease linked to variants in . Currently, there is no cure or disease altering treatment for this disease. This is, in part, due to a lack of insight into early phenotypes of BPAN progression and 's role in establishing and maintaining neurological function.

View Article and Find Full Text PDF

Absence of functional acid-α-glucosidase (GAA) leads to early-onset Pompe disease with cardiorespiratory and neuromuscular failure. A novel Pompe rat model ( ) was used to test the hypothesis that neonatal gene therapy with adeno-associated virus serotype 9 (AAV9) restores cardiorespiratory neuromuscular function across the lifespan. Temporal vein administration of AAV9-DES-GAA or sham (saline) injection was done on post-natal day 1; rats were studied at 6-12 months old.

View Article and Find Full Text PDF

The progression of Alzheimer's disease (AD) is intricately tied to the impairment of neurons, crucial for neurological functions. Despite extensive research, the precise mechanism underlying AD development remains elusive due to its multifaceted aetiology. Vitamin deficiency has emerged as a notable contributor to AD onset and progression, exerting a significant influence on brain function.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!